GEORGIAMUNE
Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.
GEORGIAMUNE
Industry:
Biotechnology Health Care Therapeutics
Founded:
2014-01-01
Address:
Gaithersburg, Maryland, United States
Country:
United States
Status:
Active
Total Funding:
0
Similar Organizations
Ablexis
Ablexis is a biotechnology company developing an innovative, next-generation platform for antibody drug discovery.
Alethia BioTherapeutics
Alethia BioTherapeutics is a biotechnology company developing monoclonal antibody-based therapeutics for cancer-associated diseases.
Applied Immune Technologies
Applied Immune Technologies is focused on developing therapeutic molecules for cancer, viral, and autoimmune diseases.Â
argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.
Asylia Diagnostics
Asylia Diagnostics - precision medicine data platform for immunotherapies
BT Biotech
BT Bio is a start-up biotech company that will develop and sell over-the-counter tests for sexually transmitted diseases.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Concortis BioSystems
Concortis is a biotechnology company creating next generation biotherapeutics using their proprietary conjugation technologies and novel
CRISP-HR Therapeutics
CRISP-HR a therapeutics company has developed a proprietary, next-generation CRISPR platform to create novel therapeutics for rare diseases.
Glycosyn
Glycosyn is a biotechnology company developing products, based on molecules.
Hadron Systems
Hadron Systems is a biotechnology company developing techniques and devices that support slow neutron therapy for cancers.
Hawkeye Bio
Hawkeye Bio is a medical technology company focused on the early detection of cancer, infectious disease and autoimmune disease.
IGXBio
IGXBio, Inc. is a biotechnology company developing advanced DNA immunotherapies for HIV infection.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Notogen
Notogen is a biotechnology company creating regenerative therapeutics for spine, orthopedic and sports medicine related conditions.
PharmaLegacy Laboratories (Shanghai) Co., Ltd.
PharmaLegacy Laboratories (Shanghai) Co., Ltd. is a provider of specialty pharmacology services in inflammation and auto-immune diseases.
ProNeurotech
ProNeurotech is a developer of neuroprotective drugs that prevent axon loss after acute injury or chronic degenerative disease.
Raqia Therapeutics
Raqia Therapeutics is a biotechnology company developing on a revolutionary immunotherapy technique called chimeric antigen receptors.
Snap Bio
Snap Bio is a pre-clinical start-up company focused on developing next generation therapeutics through a pioneering approach and platform.
Transave
Transave is a biotechnology company developing inhaled pharmaceuticals for the treatment of lung diseases.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Waypoint Bio
Waypoint Bio is a biotechnology company developing therapeutic treatments for rare genetic diseases
Current Employees Featured
Founder
Investors List
Lauder Partners
Lauder Partners investment in Venture Round - Georgiamune
More informations about "Georgiamune"
Team - Georgiamune
Prior to joining Georgiamune in October 2024, Mr. Avagliano was the Chief Business Officer of G1 Therapeutics, a commercial stage oncology biotech company, from 2019 through its acquisition in 2024. ... Prior to that, Mace led …See details»
Georgiamune - Crunchbase Company Profile & Funding
Organization. Georgiamune . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Georgiamune is a biotechnology …See details»
Georgiamune
“It’s such a privilege to be part of Georgiamune and to be joining this world-class team and organization that is making major strides in the discovery and development of much needed …See details»
Georgiamune, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Georgiamune was founded by Dr. Samir N. Khleif, a world-renowned medical oncologist and researcher in the field of immunology and cancer, based on discoveries in his lab on novel …See details»
Georgiamune Appoints Biopharma Veteran Mark Avagliano as
Nov 19, 2024 “It’s such a privilege to be part of Georgiamune and to be joining this world-class team and organization that is making major strides in the discovery and development of much …See details»
Georgiamune - Funding, Financials, Valuation & Investors
Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases. Search Crunchbase. Start Free Trial . ... How much funding …See details»
Georgiamune Inc. - VentureRadar
" Georgiamune is a biopharmaceutical company focused on reprogramming immune responses to combat cancer and autoimmune diseases. They regulate signaling pathways to restore …See details»
Georgiamune - Contacts, Employees, Board Members, Advisors
Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.See details»
Company news - Georgiamune
Aug 9, 2023 GAITHERSBURG, MD, September 24, 2024 – Today, Georgiamune Inc., a privately held, clinical-stage biotechnology company, announced that the first participant has …See details»
Georgiamune and Verily announce strategic partnership to …
Oct 26, 2023 Georgiamune was founded by Dr. Samir N. Khleif, a world-renowned medical oncologist and researcher in the field of immunology and cancer, based on discoveries in his …See details»
Georgiamune - Products, Competitors, Financials, Employees ...
Georgiamune is a biotechnology company focused on reprogramming immune responses to combat cancer and autoimmune diseases within the healthcare sector. ... “It’s such a privilege …See details»
Georgiamune Expands Cancer Treatment Pipeline with Two Novel …
May 29, 2024 Georgiamune receives U.S. FDA clearance for GIM-531 and begins phase II of clinical trial testing for GIM-122GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- …See details»
Our Investment in Georgiamune - General Catalyst
Aug 9, 2023 We believe Georgiamune's lead candidate, GIM-122, is a first-in-class, monoclonal dual-functioning antibody with a highly differentiated mechanism of action, that has the …See details»
Georgiamune - Updates, News, Events, Signals & Triggers
Jul 18, 2024 Organization. Georgiamune . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. News Insight Details. Powered by …See details»
Georgiamune Receives FDA Clearance for IND Application and …
Aug 9, 2023 Georgiamune announced the clearance of its Investigational New Drug (IND) application by the FDA for GIM-122, a dual-functioning monoclonal antibody. Furthermore, the …See details»
Georgiamune
Georgiamune receives U.S. FDA clearance for GIM-531 andcontinues to enroll patients in clinical trial testing for GIM-122. GAITHERSBURG, MD, May 29, 2024 – Today, Georgiamune Inc., a …See details»
Georgiamune | Catalio Capital Management
Georgiamune is developing novel immune checkpoint blockades to address the needs of cancer patients that do not benefit from first-generation checkpoint inhibitors, such as Merck's …See details»
GIM-0616 - Drug Targets, Indications, Patents - Synapse
GIM-0616, Initially developed by Georgiamune, Inc., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Neoplasms, Active Indication: Neoplasms ...See details»